Vyne Competitors
| VYNE Stock | USD 3.03 0.13 4.48% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Vyne Therapeutics competition on your existing holdings.
Vyne |
Vyne Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Vyne Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Vyne and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Vyne Therapeutics does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Vyne Stock performing well and Vyne Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vyne Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AKTX | 4.09 | (1.38) | 0.00 | 9.75 | 0.00 | 4.74 | 47.27 | |||
| SLRX | 4.13 | (0.43) | 0.00 | (0.28) | 0.00 | 8.79 | 27.43 | |||
| AXLA | 3.96 | (0.91) | 0.00 | 1.49 | 0.00 | 7.69 | 39.29 | |||
| MGTA | 2.62 | 0.13 | 0.00 | (0.71) | 3.40 | 5.88 | 16.99 | |||
| HSTO | 3.85 | (0.98) | 0.00 | 1.50 | 0.00 | 4.76 | 131.40 | |||
| FWBI | 5.73 | (1.84) | 0.00 | (5.24) | 0.00 | 8.65 | 65.42 | |||
| SABS | 5.71 | 0.45 | 0.06 | 1.12 | 6.39 | 17.06 | 45.73 | |||
| VCNX | 6.01 | (0.22) | 0.00 | (0.26) | 0.00 | 11.11 | 54.95 | |||
| GOVX | 5.91 | (1.43) | 0.00 | (0.72) | 0.00 | 9.26 | 77.95 | |||
| CBIO | 4.25 | 0.97 | 0.13 | (74.33) | 4.45 | 9.76 | 38.47 |
Cross Equities Net Income Analysis
Compare Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKTX | (675 K) | (2.1 M) | (1.4 M) | (3.6 M) | (9.6 M) | (45.3 M) | (18.1 M) | (27.9 M) | (27.9 M) | (21.8 M) | (17.6 M) | (17.6 M) | (7 M) | (10 M) | (10.5 M) |
| SLRX | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (39.5 M) | (34.4 M) | (21.9 M) | (5.6 M) | (7.1 M) | (12.7 M) | (31.4 M) | (12.5 K) | (13.2 K) |
| HSTO | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (22.3 M) | (24.1 M) | (29.7 M) | (17.4 M) | (18 M) | (4.9 M) | (25.8 M) | (14.4 M) | (10.5 M) | (12.4 M) | (13 M) |
| SABS | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | 20.1 M | (17.4 M) | (18.7 M) | (42.2 M) | (40.1 M) |
| VCNX | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (18.7 M) | (29.5 M) | (32 M) | (29.3 M) | (23.2 M) | (19.7 M) | (20.3 M) | (21.3 M) |
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (24.7 M) |
| UNCY | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.5 M) | (10.6 M) | (18.1 M) | (30.5 M) | (29 M) |
| PULM | (30 K) | (30 K) | (523 K) | (3.1 M) | (3.1 M) | (26.2 M) | (27.8 M) | (18.1 M) | (20.6 M) | (20.4 M) | (28.5 M) | (22.5 M) | (18.7 M) | (14.1 M) | (14.8 M) |
| CDTX | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (40.1 M) | (72.4 M) | (43.9 M) | (29.8 M) | (22.9 M) | (24.1 M) |
| PHIO | (10.2 M) | (10.2 M) | (12.9 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (12.5 M) | (7.4 M) | (8.8 M) | (8.8 M) | (13.2 M) | (11.3 M) | (10.8 M) | (11.4 M) |
| KRON | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (15.4 M) | (64.1 M) | (149.1 M) | (129.3 M) | (112.7 M) | (118.3 M) |
| VCYT | (14.4 M) | (14.4 M) | (18.6 M) | (25.6 M) | (29.4 M) | (33.7 M) | (31.4 M) | (31 M) | (23 M) | (16.5 M) | (35.8 M) | (75.6 M) | (36.6 M) | (74.4 M) | (70.7 M) |
| LGVN | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (3 M) | (3.8 M) | (17.2 M) | (19.6 M) | (21.4 M) | (20.3 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.1 M) | (22 M) | (42.4 M) | (55.3 M) | (62.7 M) | (59.5 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (114.2 K) |
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 3.5 M | (60.4 M) | (57.3 M) |
| ZVSA | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (8.9 M) | (759.1 M) | (98.3 M) | (103.2 M) |
| RNAZ | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (2.7 M) | (6.9 M) | (35.1 M) | (18.5 M) | (19.5 M) |
Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Vyne Therapeutics financial statement analysis. It represents the amount of money remaining after all of Vyne Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Vyne Therapeutics Competitive Analysis
The better you understand Vyne Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Vyne Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Vyne Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Vyne Therapeutics Competition Performance Charts
Five steps to successful analysis of Vyne Therapeutics Competition
Vyne Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Vyne Therapeutics in relation to its competition. Vyne Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Vyne Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Vyne Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Vyne Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Vyne Therapeutics position
In addition to having Vyne Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1091 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vyne Therapeutics Correlation with its peers. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.